Zeus Opens State-of-the-Art Facility

Zeus, a global leader in advanced polymer solutions, announced today that construction is almost complete on a state-of-the-art catheter manufacturing facility in Arden Hills, Minnesota. The location, scale, and on-site capabilities across R&D, design, and development will advance catheter innovation and strengthen Zeus’s strategic partnerships with OEMs and medical device customers.

“The Minnesota facility is an important step in our geographic expansion for several reasons,” said Steve Peterson, President and CEO of Zeus. “The state has a long track record in medical device innovation, and locating closer to customers will support deeper collaboration across early-stage catheter design and development. Furthermore, this facility allows us to scale catheter manufacturing significantly to meet growing global customer and market demand.”

Scheduled to open in summer 2023, this custom 75,600 square feet facility includes an advanced R&D lab and cleanroom equipped with the latest technologies to design, develop, and validate new catheter prototypes in industry-best lead times. It also brings additional capabilities in-house to Zeus, including laser cutting, ablation, and welding.

“This facility opens the door to expanding our end-to-end catheter design and manufacturing capabilities, all under one roof. It’s a big step for our customers and the industry,” said Suresh Sainath, General Manager for Zeus’ catheter solutions division. “It also represents a building block for future strategic collaboration between our catheter and polymer customers, enabling industry-defining catheter innovation going forward.”

As well as proximity to current customers, the Arden Hills, MN, location was selected for its easy access to local transportation and amenities for the company’s expanding workforce. Following an agreement with DEED as part of the Minnesota Job Creation Fund (JCF), this new facility is expected to create 100-plus new jobs in the coming years. Positions will include engineers, project managers, technicians, and product builders.

SourceZeus

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version